首页|骨瓜提取物注射液联合唑来膦酸治疗原发性骨质疏松症的临床研究

骨瓜提取物注射液联合唑来膦酸治疗原发性骨质疏松症的临床研究

扫码查看
目的 探讨原发性骨质疏松症(OP)患者应用骨瓜提取物注射液联合唑来膦酸治疗的效果.方法 回顾性选取2021年1月至2023年12月商丘市中医院收治的原发性OP患者90例为研究对象,根据治疗方案分为参考组(n=45,给予唑来膦酸治疗)、联合组(n=45,给予骨瓜提取物注射液联合唑来膦酸治疗).比较两组临床疗效、骨密度、骨钙素N端中分子片段(N-MID)、25-羟维生素D[25(OH)D]、骨碱性磷酸酶(BAP)、抗酒石酸酸性磷酸酶异体(TRACP-5b)、白细胞介素-1β(IL-1β)、白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)水平,以及不良反应发生率.结果 联合组总有效率95.56% 较参考组77.78% 高(P<0.05);联合组治疗后腰椎L1~L4、股骨颈、髋部骨密度均明显高于参考组(P<0.05);与参考组相比,联合组治疗后血清N-MID、25(OH)D、BAP水平较高,TRACP-5b水平较低(P<0.05);联合组治疗后血清IL-1β、IL-6、TNF-α水平降低幅度大于参考组(P<0.05);联合组不良反应发生情况与参考组相比差异无统计学意义(P>0.05).结论 骨瓜提取物注射液联合唑来膦酸对原发性OP患者治疗效果显著,可明显增加OP患者骨密度、改善骨代谢指标、降低血清炎症因子水平.
Clinical study on the treatment of primary osteoporosis with bone melon extract injection combined with Zoledronic Acid
Objective To explore the therapeutic effect of bone melon extract injection combined with Zoledronic Acid in patients with primary osteoporosis(OP). Methods 90 patients with primary osteoporosis admitted to Shangqiu Traditional Chinese Medicine Hospital from January 2021 to December 2023 were retrospectively selected as the study subjects.According to the treatment plan,they were divided into a reference group(n=45,treated with Zoledronic Acid) and a combination group(n=45,treated with bone melon extract injection combined with Zoledronic Acid).The clinical efficacy,bone mineral density(BMD),N-terminal mid molecular fragment of osteocalcin(N-MID),25 hydroxyvitamin D[25(OH)D],bone alkaline phosphatase(BAP),tartrate resistant acid phosphatase 5b(TRACP-5b),interleukin-1 β(IL-1 β),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α) levels,and incidence of adverse reactions between the two groups were compared.Results The clinical efficacy of the combination group was 95.56%,higher than that of the reference group(77.78%),P<0.05;After treatment,the BMD of lumbar vertebrae L1-L4,femoral neck,and hip in the combination group were significantly higher than those in the reference group(P<0.05);Compared with the reference group,the combination group had higher levels of serum N-MID,25(OH)D,and BAP after treatment,and lower levels of TRACP-5b(P<0.05);The decrease range in serum levels of IL-1 β,IL-6,and TNF-α after treatment in the combination group was greater than that in the reference group(P<0.05);There was no difference of statistical significance in the occurrence of adverse reactions between the combination group and the reference group(P>0.05). Conclusion The combination of bone melon extract injection and Zoledronic Acid has significant therapeutic effects on primary osteoporosis patients,which can significantly increase bone density,improve bone metabolism indicators,and reduce serum inflammatory factor levels.

Bone melon extract injectionZoledronic AcidPrimary osteoporosisTherapeutic effect

刘岩

展开 >

商丘市中医院药学部,河南商丘 476000

骨瓜提取物注射液 唑来膦酸 原发性骨质疏松症 疗效

2025

中国疗养医学
中国煤矿工人北戴河疗养院

中国疗养医学

影响因子:0.584
ISSN:1005-619X
年,卷(期):2025.34(1)